Kazia Therapeutics directors demonstrate confidence in company with on-market purchases
During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million end-March.
New transactions leave Kazia a vastly stronger and more substantial business, with a diversified pipeline of world-class oncology assets.
Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) directors have demonstrated their confidence in the company's biotech strategy with on-market purchases.
Non-executive director Steven Coffey acquired 7,250 shares at $1.40 per share in an indirect interest between April 30 and May 3, increasing the number of securities held in that interest to 418,250 shares with another 8,015 held in a direct interest.
Related Keywords
, Iain Ross , Steven Coffey , James Garner , Small Caps , Harma Biotech , Kazia Therapeutics Ltd , Asx Kza , Roactiveinvestors , இயேந் ரோஸ் , ஜேம்ஸ் கார்னர் , சிறிய தொப்பிகள் ,
comparemela.com © 2020. All Rights Reserved.